Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
117 results about "Metastatic breast cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumours, secondaries or stage 4 breast cancer, is a stage of breast cancer where the disease has spread to distant sites beyond the axillary lymph nodes. There is no cure for metastatic breast cancer. There is no stage after IV.
Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
InactiveUS20090061456A1Less side effectsImprove the quality of lifeDisease diagnosisBiological testingOncologyDisease progression
A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials.
Owner:VERIDEX LCC
Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
InactiveUS20070009535A1Increase ratingsImprove curing rateBiocideCarbohydrate active ingredientsZosuquidarTreatment options
The present invention relates to a method of determining P-glycoprotein expression and / or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and / or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and / or function is used to select a treatment option for the patient.
Owner:KANISA PHARMA INC
Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
Provided herein are methods, compositions and kits for the treatment of locally advanced or metastatic breast cancer or breast cancer brain metastases. The method comprises administration of 4-iodo-3-nitrobenzamide, a metabolite or salt thereof in combination with irinotecan. The method of treating locally advanced or metastatic breast cancer comprises at least one 21 day treatment cycle.
Owner:BIPAR SCI INC
Nectin 4 (N4) as a Marker for Cancer Prognosis
InactiveUS20080268476A1Rapidly characterizing the prevalence and prognostic significanceQuick analysisConnective tissue peptidesMicrobiological testing/measurementNectinOncology
The present invention relate for a method for prognosis cancer, in particular metastatic breast cancer comprising doing a dosage of Nectin 4, in a soluble form or in transmembrane form, in a sample, the presence of Nectin 4 being indicative of a cancer.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine
A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
Owner:WYETH LLC
Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
InactiveUS20150132388A1Improve permeabilityImprove solubilityPowder deliveryOrganic active ingredientsAnti estrogenDisease progression
The present invention relates to pharmaceutically acceptable complex formulae comprising complexes of Fulvestrant, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present invention have improved physicochemical properties which makes the compound orally available and makes oral administration of the compound possible in the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
Owner:DRUGGABILITY TECH IP HOLDCO
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
Owner:WYETH LLC
Antineoplastic Combinations Containing HKI-272 and Vinorelbine
A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
Owner:WYETH LLC
Cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)
Neutropenia is the dose-limiting toxicity of the tri-weekly docetaxel (Taxotere®) schedule. Here, we evaluate in Metastatic Breast Cancer (MBC) patients (N=38) a computerized method for predicting docetaxel-induced neutropenia, and use the model to identify improved docetaxel and Granulocyte Colony Stimulating Factor (G-CSF) regimens. Pharmacokinetics / pharmacodynamics (PK / PD) models were created and simulated concomitantly with a mathematical granulopoiesis model. Individual baseline neutrophil counts and docetaxel schedules served as inputs. Our trial validated the model accuracy in predicting nadir timings (r=0.99), grade 3 / 4 neutropenia (86% success) and neutrophil profiles (r=0.62). Model was robust to CYP3A-induced variability, except for slightly less accurate grade 3 / 4 neutropenia predictions. Simulations confirm smaller toxicity of the weekly docetaxel regimen than the tri-weekly one, and suggest an optimal G-CSF support for alleviating neutropenia, 60 μg / day QD×3, 6-7 days post-docetaxel, administered tri- and bi-weekly, and 4 days post weekly docetaxel>33 mg / m2.
Owner:OPTIMATA
Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
InactiveUS20070009533A1Increase ratingsImprove curing rateBiocideNervous disorderZosuquidarTreatment options
The present invention relates to a method of determining P-glycoprotein expression and / or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and / or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and / or function is used to select a treatment option for the patient.
Owner:KANISA PHARMA INC
Small-molecule inhibitors of Rac1 in metastatic breast cancer
Owner:UNIVERSITY OF PUERTO RICO
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
ActiveUS20170043035A1Decreased and no measurable affinityShrink tumorNervous disorderPharmaceutical delivery mechanismRegimenWilms' tumor
A composition comprising at least one AAV vector formulated for central nervous system delivery is described. The composition comprises at least one expression cassette which contains sequences encoding an anti-neoplastic immunoglobulin construct for delivery to the brain operably linked to expression control sequences therefor and a pharmaceutically acceptable carrier. The anti-neoplastic immunoglobulin construct may be an immunoglobulin modified to have decreased or no measurable affinity for neonatal Fc receptor (FcRn). Also provided are methods of using these constructs in preparing pharmaceutical compositions and uses thereof in anti-neoplastic regimens, particularly for primary and / or metastatic cancers of the brain.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
18F-labeled ethinyloestradiol and preparation method and application thereof
ActiveCN106977576AImprove biological activityImprove pharmacokinetic propertiesOrganic active ingredientsOrganic chemistry methodsMedicineCurative effect
The present invention relates to the field of medicinal chemistry, and in particular relates to 18F-labeled ethinyloestradiol and a preparation method and application thereof, a modifying group is introduced into ethinylestradiol, and the ethinylestradiol is labeled by 18F, and the 18F-labeled ethinyloestradiol has good bioactivity, excellent pharmacokinetic properties and good stability in vitro, can be better targeting to breast cancer ER + cells, and can be used as a PET tracer for early diagnosis or therapeutic effect evaluation of high metastatic breast cancer ER + cells. The invention also provides the preparation method of the 18F labeled ethinylestradiol, a labeling group is introduced into the ethinylestradiol as a raw material by Click reaction, and heated for being exchanged with 18F<-> under relatively mild conditions, a labeling step and purification time are simplified, the radiochemical yield of the 18F-labeled ethinyloestradiol is high, and commercial application and clinical promotion of radiolabeled compounds are facilitated.
Owner:JIANGSU INST OF NUCLEAR MEDICINE
Tumor-treating compound and application thereof
ActiveCN104926793AHas antitumor activityStrong therapeutic activityOrganic active ingredientsOrganic chemistry methodsMelanomaHalf-life
Provided in the present invention are a compound for treating tumours and a use thereof, and also provided are a compound as shown in formula I or a pharmaceutically acceptable salt thereof. The compound provided in the present invention has a high medicine peak concentration, a high medicine absorption and a long elimination half life, and can improve the efficacy of the medicine in clinical use and reduce the frequency of the dosages. The compound or the pharmaceutically acceptable salt thereof prepared by the present invention can act as a PARP inhibitor medicine, have a certain anti-tumour activity, and especially have a good therapeutic activity on triple negative, primary or metastatic breast cancer, colon cancer, uterine cancer, pancreatic cancer, lung cancer, stomach cancer, leukemia, melanoma, solid tumors or intracranial tumors, and provide a new choice for clinical medication.
Owner:HINOVA PHARM INC
Overexpression of Wnt ligands and treatment of lytic bone diseases
ActiveUS20080193515A1Preventing and reducing bone destructionRaise the ratioOrganic active ingredientsBiocideMedicineProstate cancer
The present invention is drawn to methods of repairing lytic bone lesions and tumor growth in an individual. In this regard, the present invention discloses use of a Wnt ligand either alone or in combination with anti-Wnt signaling antagonist therapy. The individuals who might benefit from such method may include but are not limited to the ones with multiple myeloma, osteoporosis, post-menopausal osteoporosis, fractures, metastatic breast cancer or metastatic prostate cancer.
Owner:BIOVENTURES LLC
Prescription and preparation method of docetaxel injection
InactiveCN102451155AEasy to manufactureImprove stabilityOrganic active ingredientsPharmaceutical delivery mechanismMetastatic small cell carcinomaPharmaceutical formulation
The invention provides a prescription and a preparation method of an anti-tumor medicament docetaxel injection which is used for early chemotherapy failure or metastatic breast cancer, late cisplatin chemotherapy failure or metastatic small cell carcinoma in the field of pharmacy. The preparation is an injection prepared by using docetaxel as an active component and adding injection auxiliary materials through heat source removing, degerming and alcohol volatilization. Aiming at the overcoming the defect of a medicinal preparation using docetaxel as the active component, the invention provides the prescription and preparation method of the docetaxel injection. The preparation prepared by virtue of the method is excellent in stability and convenient in preparation, so that the medicament safety and the patient adaptability are improved.
Owner:双鹤药业(海南)有限责任公司
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
InactiveUS20070009532A1Strong therapeutic activityImprove completion rateBiocideAntibody ingredientsAntibody conjugateRecurrent acute
The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such as Mylotarg. The invention is also directed to pharmaceutical formulations comprising zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML) and metastatic breast cancer.
Owner:KANISA PHARMA INC
Methods of detecting and treatment of cancers using scutellaria barbata extract
An extract of Scutellaria Barbata D. Don is effective in the arrest of cancer cell growth. The extract of Scutellaria Barbata D. Don may be used as a therapeutic treatment for patients who have been identified as having cancer. In some situations, a patient is identified as having a type of cancer by detecting the presence of a biomarker for that cancer in the patient's system and by further determining the level of that biomarker in the patient's system. If the level of the biomarker is above a predetermined threshold level for that biomarker, the patient may be diagnosed with cancer. Subsquently, treatment using an extract of Scutellaria Barbata D. Don may begin. Biomarkers of interest in the detection of the presence of metastitic breast cancer include 8-oxoguanine and lactate dehydrogenase.
Owner:BIONOVO
Ctc biomarker assay to combat breast cancer brain metastasis
InactiveUS20140322356A1Frequent and intense monitoringHeavy metal active ingredientsMicrobiological testing/measurementCirculating cancer cellOncology
Embodiments of the present invention concern methods related to treating, prognosticating and / or diagnosing at least brain metastatic breast cancer. Embodiments of the methods include characterizing circulating tumor cells for the presence or absence of EpCAM and, upon identification of EpCAM negative cells and identification of the status of other markers (such as heparanase and / or Notch1, for example), treating the individual based on the determination of the characterization.
Owner:BAYLOR COLLEGE OF MEDICINE
Methods for the treatment of breast cancer
Owner:SYNDAX PHARM INC
Novel Small-Molecule Inhibitors of Rac1 in Metastatic Breast Cancer
A novel inhibitor of Rac activity based on the structure of the established Rac / Rac-GEF inhibitor NSC23766 is discloses. The compound EHop-016, with an IC50 of 1.1 μM, is a 100-fold more efficient inhibitor of Rac activity than NSC23766. EHop-016 is specific for Rac1 and Rac3 at concentrations ≦5 mM. At higher concentrations, EHop-016 inhibits the close homolog Cdc42. In MDA-MB-435 cells, EHop-016 (≦5 mM) inhibits the association of the Rac-GEF Vav2 with a nucleotide-free Rac1(G15A), which has a high affinity for activated GEFs. EHop-016 does not affect the association of the Rac-GEF Tiam-1 with Rac1(G15A) at similar concentrations. EHop-016 also inhibits the Rac activity of MDA-MB-231 metastatic breast cancer cells and reduces Rac-directed lamellipodia formation in both cell lines. EHop-016 decreases Rac-downstream effects of p21-activated kinase (PAK)1 activity and directed migration of metastatic cancer cells. At low concentrations (<5 μM), EHop-016 does not affect cell viability.
Owner:UNIVERSITY OF PUERTO RICO
Epithelial-mesenchymal transition in circulating tumor cells (CTCS) negatives for cytokeratin (CK) expression in patients with non-metastatic breast cancer
The inventors of the present invention have surprisingly discovered that EGFR expression in nonmetastatic breast cancer patients with CK-negative CTCs could induce EMT process. A simultaneous detection of both EGFR and EMT markers (VIM and Slug) in CTCs might improve prognostic or predictive information in patients with operable breast cancer.
Owner:SERVICIO ANDALUZ DE SALUD (SAS) +1
Methods for the treatment of breast cancer
Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
Owner:SYNDAX PHARM INC
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
ActiveUS10780182B2Decreased and no measurable affinityConducive to survivalNervous disorderPharmaceutical delivery mechanismRegimenIntravenous gammaglobulin
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Anticancer drug complex, and preparation method and application thereof
ActiveCN109833478AImprove solubilitySmall toxicityOrganic active ingredientsPharmaceutical non-active ingredientsDense Core VesiclesSolvent
The invention discloses an anticancer drug complex. The anticancer drug complex has a core-shell structure, wherein a core of the core-shell structure is an anticancer active component, and a shell ofthe core-shell structure is formed by combining at least one of neuropeptide Y or a subtype thereof with a zeolite imidazate skeleton structure material. The invention also discloses a preparation method of the anticancer drug complex, wherein the method comprises the following steps: 1) dissolving a zinc source, 2-imidazolaldehyde and the anticancer active component in a solvent respectively, toobtain three solutions; 2) mixing the three solutions in the step 1 evenly, carrying out centrifugal separation and drying; and 3) dispersing the dried product in the step 2) in a solvent, adding atleast one of neuropeptide Y or the subtype thereof, and carrying out a stirring reaction for 12-72 h. The invention also discloses an application of the anticancer drug complex in preparation of drugsfor cancer treatment, preferably, cancer includes breast cancer with high expression of neuropeptide Y1 receptors and high metastatic breast cancer.
Owner:NINGBO INST OF MATERIALS TECH & ENG CHINESE ACADEMY OF SCI
Method of treatment for early stage cancer
InactiveUS20080269135A1Easy to solveEarly stageBiocidePeptide/protein ingredientsDiseaseAcquired resistance
This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of dormancy, that surgery to remove a primary tumor can induce metastatic growth, and that women with Down Syndrome rarely get breast cancer. It elevates the level of an antiangiogenic drug produced by chromosome 21 preferably Endostatin in plasma preferably at least one day prior to surgery and kept at that high level preferably indefinitely. The therapy specifically excludes drugs that significantly inhibit the VEGF pathway since that is important for wound healing. This method will prevent results of surgery from stimulating tumor growth and angiogenesis of micrometastatic disease that is much easier to prevent than control after the fact. This can be done indefinitely since there is no acquired resistance that develops, as happens in most cancer therapies.
Owner:RETSKY MICHAEL W
Antitumor Combination Including Cabazitaxel and Capecitabine
The invention relates to a method of treatment of metastatic breast cancer in a patient progressing after a previous anthracycline and / or taxane treatment, said method comprising administering to said patient a combination of antitumor agents comprising cabazitaxel and capecitabine, wherein each of said antitumor agents, independently, may be in the form of a base, in the form of a pharmaceutically acceptable acid salt or in the form of a hydrate or solvate.
Owner:SANOFI SA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com